Amgen's Marc de Garidel elected EBE president
Published on: 14/07/10
Brussels-based industry association the European Biopharmaceutical Enterprises has elected Amgen’s Marc de Garidel as its new president.
He will serve for a two-year term and takes over the post from Genzyme’s senior vice president of global market access Dr Carlo Incerti, who will continue to sit on the EBE board as vice president
Mr de Garidel is vice president south region of Amgen International, based in Zug, Switzerland and has served on the EBE board as vice president and treasurer since April 2006.
Commenting on his election, Mr de Garidel said he was eager to further drive the development of EBE as a strong voice for biopharmaceuticals in Europe.
The EBE has also elected a number of other industry executives to its board of directors including: Dr Roberto Gradnik (executive VP, Merck Serono), Dr Edwin Moses (chairman and chief executive of Ablynx), Søren Tulstrup (president and chief executive of Santaris Pharma), Dr Ralf Schumacher (head of biologics research at Roche) and Dr Ignacio Faus (chief executive of Palau Pharma).
Mission Statement
InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma jobs, pharma events, and pharma service company listings.
Site content is produced by our editorial team for InPharm.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
